



Second Circular and Provisional Conference Program

A New International Conference

Cancer Vaccines/Adjuvants/Delivery for the Next Decade

CVADD 2005 – 5-7 September 2005
Pestana Palace Hotel, Lisbon, Portugal

Scientific Advisory Panel

Malcolm Mitchell (Van Elslander Cancer Center, Michigan, USA)
Lindy Durrant (University of Nottingham, UK)
John Samuel (University of Alberta, Edmonton, Canada)
Jan Holmgren (University of Gothenberg, Sweden)
Robert Rose (University of Rochester, USA)
Joyce Taylor-Papadimitriou (Cancer Research UK, London, UK)
Dave Hoon (John Wayne Cancer Institute, Santa Monica, USA)
Suzy Scholl (Institut Curie, Paris, France)
Jedd Wolchok (Memorial Sloan-Kettering Cancer Center, New York, USA)
Hans Strander (Karolinska Hospital, Stockholm, Sweden)
Matthew Downham (Protherics PLC, Runcorn, UK)

Conference Scope/Topics

In the past there has been inadequate attention paid to cancer immunotherapy/vaccine issues. However this field of vaccine research is now emerging as one of the major issues occupying the cancer community.

CANCER VACCINES/ADJUVANTS/DELIVERY FOR THE NEXT DECADE – CVADD 2005 is a new and important international conference that will offer a forum for researchers into cancer vaccines to meet and discuss the latest developments/initiatives in this important field of vaccine research.

Closing date for poster abstract submissions Friday 1st July 2005



Register securely on-line at: www.meetingsmanagement.com/cvadd_2005

*Graphic courtesy of Jorgen de Jonge (University of Groningen, The Netherlands)

CANCER VACCINES/ADJUVANTS/DELIVERY
FOR THE NEXT DECADE

Provisional Conference Program – Monday 5th September 2005

08.55–09.00

Welcome & Opening Remarks

Hans Strander (*Karolinska Institute, Stockholm, Sweden*)

SESSION 1:

OPENING PLENARY SESSION

Moderator: Hans Strander

(*Karolinska Institute, Stockholm, Sweden*)

09.00–09.45

'A critical assessment of the progress of cancer vaccines'

Vincenzo Bronte (*Istituto Oncologico Veneto, Padova, Italy*)

09.45–10.30

'Optimizing cancer vaccination strategies in patients'

Hakan Mellstedt

(*Cancer Centre Karolinska, Stockholm, Sweden*)

10.30–11.00

Coffee Break and Poster Set-up

11.00–11.45

'Immunotherapeutic targets and cancer vaccination'

Robert Hawkins

(*Paterson Institute for Cancer Research, Manchester, UK*)

11.45–12.30

'Cancer vaccines as a therapeutic strategy'

Angus Dalgleish

(*St. George's Hospital Medical School, London, UK*)

12.30–14.00

Lunch Break & Posters

SESSION 2:

PLENARY SESSION

Moderator: Jan Holmgren (*University of Gothenburg, Sweden*)

14.00–14.30

'Autologous cellular vaccines: an overview'

Volker Schirmmayer

(*German Cancer Research Center, Heidelberg, Germany*)

14.30–14.50

'Improvement of long-term patient survival upon antitumor vaccination with an autologous tumour cell vaccine modified by virus infection'

Volker Schirmmayer

(*German Cancer Research Center, Heidelberg, Germany*)

14.50–15.20

'Developments with GSK cancer vaccines programme'

Vincent Brichard (*GSK Biologicals, Rixensart, Belgium*)

15.20–15.50

'Cytolytic T-lymphocyte responses with relevance to cancer vaccination strategies'

Cornelius J.M. Melief

(*University of Leiden Medical School, Leiden, The Netherlands*)

15.50–16.20

'Overcoming cancer-induced T regulatory cell inhibitory activity'

John Samuel (*University of Alberta, Canada*)

16.20–16.40

Tea Break & Posters

SESSION 3:

PEPTIDE VACCINES

Moderator: John Samuel (*University of Alberta, Canada*)

16.40–17.00

'Exploration of the course of the p53 specific immune response during standard treatment and p53 based vaccination for ovarian cancer'

H.W. Nijman, A. Lambeck, S.H. van der Burg, R. Offringa,

H. Klip, I. Hamming, H. Hollema, A.G.J. van der Zee,

C.J.M. Melief and C.A.H.H. Daemen

(*University Medical Centre Leiden, The Netherlands*)

17.00–17.20

'VEGF as a potential target for a novel peptide-carrier protein based immunotherapeutic vaccine to control cancer metastasis'

Matthew Downham (*Protherics Molecular Design Ltd, UK*)

17.20–17.40

'Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein'

X. Preville, D. Ladant, B. Timmerman and C. Leclerc

(*BT Pharma Prologue-Biotech, Labège-Innople, France*)

17.40–18.00

'Development of multiple-peptide cancer vaccines'

Harpreet Singh et al.

(*IMMATICS Biotechnologies GmbH, Tübingen, Germany*)

18.00–18.45

WORKSHOP A: Title to be confirmed

Facilitator: Dave Hoon (*John Wayne Cancer Institute, USA*)

Evening:

Poster Session/Reception

CVADD 2005 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom

Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516

Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/cvadd_2005

SESSION 4:

DNA VACCINES

Moderator: Dave Hoon (*John Wayne Cancer Institute, USA*)

08.30-09.00

'Mechanisms to modify the immune response elicited by polymer encapsulated DNA and a clinical update'

Mary Lynne Hedley

(*MGI Pharma Inc, Princeton, New Jersey, USA*)

09.00-09.30

'Optimizing DNA vaccines for cancer'

Jedd Wolchok

(*Memorial Sloan Kettering Cancer Center, New York, USA*)

09.30-10.00

'MUC1 based immunogens: DNA based formulations and importance of glycoform'

Joyce Taylor-Papadimitriou

(*Cancer Research UK Breast Cancer Biology Group*)

10.00-10.20

'DNA immunization against tumor antigens during homeostatic T-cell proliferation provides tumor-free survival in an established model'

M.-A. Perales, A. Diab, A.D. Cohen, D. Huggins, V.M. Hubbard, A. Kochman, M. Engelhorn, J.A. Guevara-patino, J.D. Wolchok, M. van den Brink and A N. Houghton

(*Memorial Sloan-Kettering Cancer Center, New York, USA*)

10.20-10.40

'Mechanism of immunity after vaccination with tumor endothelial marker 8 DNA'

P.D. Gregor, P. Felicetti, F. Orlandi, S. Montgomery, M. Mennecozzi, F. Venanzi, A. Concetti, A.N. Houghton and J.D. Wolchok

(*Memorial Sloan Kettering Cancer Center, New York, USA*)

10.40-11.00

Coffee Break & Posters

11.00-11.45

'Targeting tumor endothelial cells with DNA vaccination can confer synergy between anti-vascular vaccines and tumor vaccines'

Rolf Kiessling (*Karolinska Institute, Stockholm Sweden*)

SESSION 5:

RECOMBINANT VIRAL VACCINES

Moderator: Jedd Wolchok

(*Memorial Sloan Kettering Cancer Center, New York, USA*)

11.45-12.05

'CTL epitope delivery on VLP carriers: enhanced immunogenicity by cross priming and multivalency'

Alison A. McCormick, Sherri Wykoff-Clary, Patricia C. Edwards, Mark L. Smith, Greg P. Pogue and Kenneth E. Palmer

(*Large Scale Biology Corporation, Vacaville, California, USA*)

12.05-12.25

'Non-cytopathic replicon based on the Flavivirus, Kunjin for the generation of long-lived protective CD8+ T cell responses'

I. Anraku, R. Linedale, G. Pijlman, N. Kondratieva, A.A. Khromykh and A. Suhrbier

(*Queensland Institute of Medical Research, Brisbane, Australia*)

12.25-12.45

'Incorporation of tumor-associated MAGE-3 epitope into virus-like particles'

Reinis Balmaks, Paul Pumpens and Andris Kazaks

(*Biomedical Research and Study Centre, Riga, Latvia*)

12.45-14.00

Lunch & Posters

14.00-14.45

'Carbohydrate vaccines: From small cell lung cancers to Group B meningococci'

Philip Livingston

(*Memorial Sloan Kettering Cancer Center, New York, USA*)

SESSION 6:

DENDRITIC CELL VACCINES

Moderator: Matthew Downham (*Protherics PLC, Runcorn, UK*)

14.45-15.15

'Fc targeting of activated dendritic cells in vivo'

Lindy Durrant (*University of Nottingham, UK*)

15.15-15.35

'Highly efficient expression of human dendritic cells after transduction with a fiber-modified adenoviral vector containing MUC1 cDNA induces tumour specific expression of MUC1'

E. van Leeuwen, S. Cloosen, B. Senden, U. Mandel, H. Clausen, W. Germeraard and G.M.J. Bos

(*University Hospital Maastricht, Maastricht, The Netherlands*)

15.35-15.55

'Strong, persistent Melan-A/MART-1-peptide-specific immune responses after dendritic cell vaccination of tumor-free stage II melanoma patients'

Christian Becker, Andrea Tuettenberg, Eva Hüter, Jürgen Knop, Alexander Enk and Helmut Jonuleit (*Department of Dermatology, Johannes Gutenberg-University, Germany*)

15.55-16.30

Tea Break & Posters

16.30-17.00

'Phase I and IB trials of murine tyrosinase + human GM-CSF DNA vaccination in dogs with advanced malignant melanoma'

Philip J. Bergman et al.

(*Memorial Sloan-Kettering Cancer Center, New York, USA*)

17.00-18.00

WORKSHOP B: Title to be confirmed

Facilitator: To be confirmed

Evening:

Free Time For Delegates

SESSION 7:

NEW ADJUVANTS/DRUGS FOR CANCER VACCINES

Moderator: Joyce-Taylor-Papadimitriou
(Cancer Research UK, London, UK)

08.30-09.00

'Vaccine adjuvants to improve cancer control'

David B. Hoon (John Wayne Cancer Institute, Santa Monica, USA)

09.00-09.30

'IC31 – a promising adjuvant candidate for use in peptide-based cancer vaccines'

Karen Lingnau (InterCell AG, Vienna, Austria)

09.30-09.50

'Recombinant human IL-18 as immunotherapeutic agent in cancer'

Danuta Herzyk, Jeanne Soos, Mohammed Dar and Zdenka Jonak
(GlaxoSmithKline Pharmaceuticals, King-of-Prussia, Pennsylvania, USA)

09.50-10.10

'Immunotherapy as an adjunct to reovirus administration in prostate cancer treatment'

J.C.L. Spurrell, A. Kim and D.G. Morris
(Alberta Cancer Board, Calgary, Alberta, Canada)

10.10-10.30

'Evaluation of anti tumor efficacy of high density expression of cancer peptides and immunomodulators on the surface of the bacterium caulobacter crescentus'

J. Smit, J.N. Nomellini, P.K. Bhatnagar, A. Awasthi and M.R. Suresh (University of British Columbia, Vancouver, Canada)

10.30-10.50

'Epitope-drug conjugates in the targeted immunotherapy of B-cell leukemias'

Michael A. Firer (College of Judea and Samaria, Ariel, Israel)

10.50-11.10

Coffee Break & Posters

SESSION 8:

NEW DELIVERY SYSTEMS FOR CANCER VACCINES

Moderator: John Samuel (University of Alberta, Canada)

11.10-11.40

'Vaccine/adjuvant delivery systems for cancer therapy'

Philippe Moingeon (Stallergenes SA, Antony, France)

11.40-12.00

'Immunostimulatory colloidal delivery systems for cancer vaccines'

S. Hook, D. Lendemans, T. Hennessy, W. McBurney and T. Rades
(University of Otago, Dunedin, New Zealand)

12.00-12.20

'Pre-clinical and clinical results from targeting gangliosides in breast cancer: the more abundant NacGM3 vs the tumour-specific NGcGM3'

L.E. Fernandez, A de la Torre, R. Lazo, M. Labrada, G. Saurwz, Y. Bebelagua, E. Santiesteban, M.C. Arango, A. Carr and R. Perez
(Centre of Molecular Immunology, Havana, Cuba)

12.20-14.00

Lunch Break & Posters

SESSION 8 (Continued):

Moderator: Dave Hoon (John Wayne Cancer Institute, USA)

14.00-14.30

'Development of ProMune, an immunostimulatory CpG oligodeoxynucleotide for therapy of cancer in vaccines or in combination with chemotherapy'

Heather Davis (Coley Pharmaceuticals, Ottawa, Canada)

14.30-15.00

'Anticancer activity of mycobacterial cell wall-DNA complex (MCC): immune stimulant, immune adjuvant and direct anticancer activities'

Mario C. Filion and Nigel C. Phillips
(Bioniche Inc., Montreal, Canada)

15.00-15.20

'Delivery of tumour antigens and cytotoxic T cell epitopes using a membrane translocating peptide induces cellular and protective immune responses'

Dodie S. Pouniotis, Geoffrey A. Pietersz, Peter J. VanMannen, Rene W. Andriessen, Jodie Lodding, Pei-xiang Xing, Ian F.C. McKenzie, Bruce E. Loveland and Vasso Apostolopoulos
(The Austin Research Institute, Heidelberg, Victoria, Australia)

15.20-15.40

'Particulate structures of the VP1-coat protein of murine polyomavirus: Immunostimulatory carriers for the efficient delivery of CD8 T cell epitopes derived from tumour antigens'

Juergen Hess, Marc Brinkman, Torsten W. Schulz and Christian Reiser (Responsif GmbH, Erlangen, Germany)

15.40-16.00

Tea Break & Posters Breakdown

SESSION 9:

CLOSING PLENARY SESSION

Moderator: Hans Strander

(Karolinska Institute, Stockholm, Sweden)

16.00-16.20

'Regulatory Issues for Cancer Vaccines'

Thea Sesardic (NIBSC, Potter Bar, UK)

16.20-17.00

'Future developments and prospects for cancer vaccines'

Drew M. Pardoll (Johns Hopkins University, Baltimore, USA)
To be confirmed

17.00-17.05

Closing Remarks

* THIS PROGRAM IS CORRECT AT TIME OF PRINTING. HOWEVER THE ORGANIZERS RESERVE THE RIGHT TO MAKE ANY ALTERATIONS THAT MAY BE REQUIRED IN THE INTERESTS OF THE CONFERENCE PROGRAM.

CVADD 2005 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/cvadd_2005

Provisional Conference Program – Poster Session

'Polysaccharides from the *Lentinus edodes* in experimental cancer vaccinotherapy'

A.B. Artamova and V.O. Shlyakhovenko

(National Academy of Sciences of Ukraine, Kiev, Ukraine)

'Hepatitis C DNA vaccine with CpG–alum adjuvants for prevention and immunotherapy of hepatocellular carcinoma'

A. Karami, N. Rastgoo, M. Ebrahimi, E. Aflaki and F. Khatami

(Bagyatallah University of Medical Science, Tehran, Iran)

Future Meetings

IMMUNOPOTENTIATORS IN MODERN VACCINES – IMV 2005

18–20 MAY 2005, MALAGA, SPAIN

PLANT-BASED VACCINES & ANTIBODIES – PBVA 2005

8–10 JUNE 2005, PRAGUE, CZECH REPUBLIC

CANCER VACCINES/ADJUVANTS/DELIVERY FOR THE NEXT DECADE – CVADD 2005

5–7 SEPTEMBER 2005, LISBON, PORTUGAL

VACCINATION, INFECTION & AUTOIMMUNITY: MYTH & REALITY – VIAMR 2005

26–28 OCTOBER 2005, LAUSANNE, SWITZERLAND

TB VACCINES FOR THE WORLD – TBV 2006

19–21 APRIL 2006, VIENNA, AUSTRIA

HUMAN ANTIBODIES & HYBRIDOMAS – HAH 2006

10–12 MAY 2006, MONTEGO BAY, JAMAICA

MODERN VACCINES/ADJUVANTS & DELIVERY SYSTEMS – MVADS 2006

12–14 SEPTEMBER 2006, LONDON, UK

INFLUENZA VACCINES FOR THE WORLD – IVW 2006

18–20 OCTOBER 2006, VIENNA, AUSTRIA

FROM GENOMES TO PROTECTIVE ANTIGENS – DESIGNING VACCINES – GPADV 2006

15–17 NOVEMBER 2006, PRAGUE, CZECH REPUBLIC

For more information on the above meetings please contact John Herriot at Meetings Management

(Email: jherriot@meetingsmgmt.u-net.com)

CVADD 2005 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom

Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516

Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/cvadd_2005

Information for Delegates

REGISTRATION

Delegates should register for CVADD 2005 by completing the form provided on the back page of this brochure. The completed Conference Registration Form plus payment (payment in £ Pounds Sterling) should be sent to the CVADD 2005 Conference Manager – Caroline Sumner at Meetings Management. The CVADD 2005 Conference Registration Desk will be open from 7.30am on Monday 5th September 2005. **Delegates can also register securely on-line at: www.meetingsmanagement.com/cvadd_2005**

VENUE & ACCOMMODATION

The venue for CVADD 2005 is the Pestana Carlton Palace Hotel, Lisbon, Portugal. Located 10 kilometres from Lisbon International Airport and just a few minutes from the city centre and its many sights and cultural attractions. The hotel incorporates a nineteenth century palace, now fully restored to its former glory, with two new wings of contemporary architecture and is classified as a national monument. The palace gardens have also been classified as a national monument and are lush with many subtropical trees and plants surrounding the outdoor swimming pool. Nearby, the health club offers a fully equipped gymnasium, a spacious indoor pool, sauna, Turkish bath, jacuzzi and Scottish showers. Visit the hotels website: www.pestana.com for the full range of facilities available on site.

The organizers have negotiated special discounted accommodation rates for CVADD 2005 delegates at the Carlton Palace Hotel. Please use the Accommodation Booking Form provided in this brochure to qualify for the special rates.

Poster Papers

Late poster paper submissions are invited and prospective authors should submit a one page abstract of their poster(s) to the Conference organizers (Meetings Management) for consideration. Please send your poster for the attention of John Herriot (E-mail: jherriot@meetingsmgmt.u-net.com) at Meetings Management. **Late poster abstracts should be submitted by Friday 1st July 2005.**

PUBLICATION

A CD ROM of final programme and abstracts of all presentations, oral and poster, will be distributed to delegates when they register at the conference.

TABLE TOP EXHIBITION

Table Top Exhibition space is available at the meeting. Exhibitors can showcase their products or services by reserving a table top exhibit. The exhibit area will be located adjacent to the main conference area where all refreshments breaks will be taken to ensure maximum traffic of conference delegates. If you are registering for the conference, you can reserve a table for £995. If you do not wish to attend the conference sessions, you can reserve a table for £1995 (includes admission to all meals/receptions by one company representative).

PLEASE NOTE: If you wish to have additional representatives

on your table top exhibit there will be an additional charge for catering levied per head. Please contact the Conference Manager for this additional price.

Please make your bookings and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Table Top Exhibition facilities at CVADD 2005 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com)

DELEGATE PACK INSERT SERVICE

Company literature/brochures/conference brochures may be distributed to delegates as part of the documentation issued on arrival/registration. One insertion in the CVADD 2005 delegate pack is priced at £395. Please make your booking and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Delegate Pack Insertion services at CVADD 2005 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com)

PLEASE NOTE: Literature for distribution to CVADD 2005 delegates is subject to approval by the conference organizers.

INSURANCE & CANCELLATION

The organizers cannot be held responsible for any personal accident or damage to their private property of participants at CVADD 2005. The organizers strongly urge participants to ensure they have adequate travel and personal insurance cover before they depart for the conference. The organizers cannot be held liable for any costs incurred should the conference be cancelled for any reason. Maximum notice of cancellation will be given by the organizers to all pre-registered delegates.

PROGRAM

The CVADD 2005 Scientific Advisory Panel and the CVADD 2005 Conference Organizers reserve the right to alter any part of the published conference program if this is necessitated by any circumstances outside their control. All efforts will be made to keep any such changes to a minimum. The program published in the brochure was correct at the time of going to press.

CANNOT ATTEND?

If you and your colleagues are unable to attend the conference, the conference materials (CD ROM of abstracts, speaker handouts, late abstracts, attendee list, pack materials and literature) are available for purchase. While not intended as a substitute for actual attendance, these materials would at least provide a documentary record of the event and allow you to keep you or your organization's library up to date. The cost of providing this non-attendee package is £345 (including postage and packing). To order this package from Meetings Management please use the relevant section in the Delegates Registration Form on the back page of this brochure.

ANY QUESTIONS?

For further information and assistance, please contact: Caroline Sumner CVADD 2005 Conference Manager (details below).

CVADD 2005 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/cvadd_2005

Sponsors

The CVADD 2005 Scientific Advisory Panel and the organizers would like to acknowledge the support of the following sponsors:



Poster Papers – Late Submissions

Additional poster paper submissions are welcomed and prospective authors are invited to submit one page abstracts to the CVADD 2005 Conference Organizers (Meetings Management) for consideration.

Please e-mail your poster abstracts to: John Herriot
(jherriot@meetingsmgmt.u-net.com)
or by fax on +44 (0)1483 428516

**LATE POSTER ABSTRACTS SHOULD BE SUBMITTED
BY FRIDAY 1ST JULY 2005**

Table Top Exhibition

Table top exhibition space is available at CVADD 2005.

Exhibitors can showcase their products/literature or services by reserving a table top exhibit (or exhibit their own display boards) during the conference.

To reserve your table top/display space at CVADD 2005 please use the relevant section in the Delegate Registration Form at the back of this brochure.

Hotel Accommodation Form for CVADD 2005

To make your hotel reservation please fax or mail the completed form to the **RESERVATIONS DEPARTMENT** (this form must be used to qualify for the special conference rate and is also available for three days prior to and three days after the conference).

PESTANA CARLTON PALACE HOTEL

Rue Jau, 54, 1300-314, Lisbon, Portugal
Telephone: +351 21 361 5600 Fax: +351 21 361 5601
Web: www.pestana.com

- Single €240
 Double/Twin €260

Rates are per night and are inclusive of American breakfast, service charge and taxes. Reservations must be accompanied by a first night room cash deposit, or guaranteed with a major credit card. In the event of cancellation deposits are refundable up to 6 weeks prior to arrival. In the event of cancellation less than six weeks prior to arrival the total amount applicable for your entire stay will be chargeable. This also applies to no shows.

Important: Hotel reservations and arrangements are the sole responsibility of the delegate. Rooms have been reserved specifically for CVADD 2005 at discounted rates. To benefit from the special conference room rates please make all necessary reservations before the cut off date of 24th July 2005. After this date rooms will be subject to availability. If your travel dates should change after this form has been submitted, please notify the hotel immediately.

Family Name Title

First Name

Job Title

Organization

Address

Post/Zip Code Country

Tel Fax

E-mail

Passport No Expiry Date

Place of Issue Date of Issue

Arrival Date Flight ETA

Departure Date Flight ETA

CREDIT CARD GUARANTEE

To: Amex VISA MasterCard

Card No.

Expiry Date

Cardholders Name

Cardholders Signature

FOR HOTEL USE ONLY

Booking is confirmed/not confirmed

Acknowledged by Date

Remarks

CVADD 2005 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/cvadd_2005

